 |
 |
Ray, thank you for all the research you have done. have you come across a doctor in Mexico by the name of MORALES who is administering stem cells? Keep up the good work. ----- Original Message ----- From: "rayilynlee" <[log in to unmask]> To: <[log in to unmask]> Sent: Monday, February 19, 2007 12:59 PM Subject: PD Research in Israel > TAU Research Leads to Next Stage in New Parkinson's Treatment > > BrainStorm, a company developed on research licensed from Tel Aviv > University, announced last week that it has started its animal model study > on stem cell treatments against Parkinson's disease. The study is being > carried out in collaboration with the Center for Applied Medical Research > (CIMA) of the University of Navarra in Pamplona, Spain. The team at the > Movement Disorders Unit at the University has over 20 years experience in > researching and applying new therapies to treat Parkinson's Disease, and > anticipates being among the first to use BrainStorm's technology to treat > patients in its own University Hospital. > BrainStorm's Chief Medical Advisor is Prof. Melamed - a world-renowned > expert in the field of neurodegenerative diseases - particularly on > Parkinson's disease. Prof. Melamed has served as head of the Neurology > Department at the Rabin Medical Center and Tel Aviv University since 1987. > Throughout his career, Prof. Melamed has specialized in neurology, holding > senior positions at the National Hospital (London) and at the Laboratory > of > Neuroendocrine Regulation (Massachusetts). He is a past president of the > Israel Neurological Association and former director of the National > Parkinson Foundation (USA). Prof. Melamed is a member of the Scientific > Committee of the Michael J Fox Foundation for Parkinson's Research. > In addition to moving ahead with the company's Parkinson's Disease > program, > Prof. Melamed is also helping BrainStorm progress with pre-clinical trials > applying the company's stem cell technology to the treatment of ALS and > Multiple Sclerosis. > BrainStorm holds rights to develop and commercialize the technology > through > an exclusive, worldwide licensing agreement with Ramot at Tel Aviv > University Ltd., the technology transfer company of Tel Aviv University. > The > Company's initial focus is on Parkinson's disease, although its technology > has promise for treating several others diseases including MS, ALS, > Huntington's disease and strokes. > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > > > -- > No virus found in this incoming message. > Checked by AVG Free Edition. > Version: 7.5.441 / Virus Database: 268.18.2/692 - Release Date: 2/18/2007 > 4:35 PM > > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn